Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in Myanmar
<b> </b>Myanmar is an endemic country for the Japanese encephalitis virus (JEV), and the SA-14-14-2 live-attenuated JEV vaccine was first introduced as a catch-up vaccination campaign in 2017. To determine the effectiveness of vaccination by means of neutralizing antibody titers against...
Main Authors: | Mya Myat Ngwe Tun, Aung Kyaw Kyaw, Khine Mya Nwe, Shingo Inoue, Kyaw Zin Thant, Kouichi Morita |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/6/568 |
Similar Items
-
The burden of Japanese encephalitis, the catch-up vaccination campaign, and health service providers’ perceptions in Myanmar: 2012–2017
by: Aung Ye Naung Win, et al.
Published: (2020-03-01) -
Detection of East/Central/South African Genotype of Chikungunya Virus in Myanmar, 2010
by: Mya Myat Ngwe Tun, et al.
Published: (2014-08-01) -
Emergence of a Novel Dengue Virus 3 (DENV-3) Genotype-I Coincident with Increased DENV-3 Cases in Yangon, Myanmar between 2017 and 2019
by: Aung Min Soe, et al.
Published: (2021-06-01) -
Envelope Protein Mutations L107F and E138K Are Important for Neurovirulence Attenuation for Japanese Encephalitis Virus SA14-14-2 Strain
by: Jian Yang, et al.
Published: (2017-01-01) -
Burden of Stroke in Myanmar
by: Narayanaswamy Venketasubramanian, et al.
Published: (2021-05-01)